Cardozo AJC, Valenzuela PJA, Arias JL, Salcedo R

Language: Spanish
References: 7
Page: 35-40
PDF size: 409.09 Kb.

ABSTRACT

We present the experience of a hospitalized case receiving treatment for SARS-CoV-2 infection who during his hospitalization course developed gastrointestinal complications, specifically colonic, associated with vasculitis, perhaps caused by the infection per se by the virus or the medications used in management. The objective of sharing this experience is to contribute to the learning and discussion about the gastrointestinal complications that occur during SARS-CoV-2 infection, which, when they go unnoticed or a late diagnosis is made, subsequently cause difficulties in management or worsen the quality of life of our patients. In our case, the diagnosis was made incidentally, suspecting a colonic perforation after colonoscopy, and the patient was taken to the emergency operating room 12 hours after the procedure with intraoperative findings of inflammatory data with a longer evolution time than expected for 12 hours of drilling. Studies carried out, in-hospital evolution, surgical and pathological anatomy findings are discussed. The discussion arises about the presence of spontaneous intestinal perforations associated with vasculitis or localized ischemia, although it is still unknown whether they are caused by the virus infection or by the management protocols used to date, as has been mentioned in other studies.

REFERENCES

1. Estevez-Cerda SC, Saldaña-Rodríguez JA, Alam-Gidi AG et al. Severe bowel complications in SARS-CoV-2 patients receiving protocolized care. Rev Gastroenterol Mex (Engl Ed). 2021; 86 (4): 378-386. doi: 10.1016/j.rgmxen.2021.08.009.

2. Gonzálvez Guardiola P, Díez Ares JÁ, Peris Tomás N et al. Perforación intestinal en paciente COVID-19 en tratamiento con tocilizumab y corticoides. A propósito de un caso [Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case]. Cir Esp (Engl Ed). 2021; 99 (2): 156-157. Spanish. doi: 10.1016/j.ciresp.2020.04.030.

3. Al Argan JR, Alqatari SG, Al Said Ah et al. Gastrointestinal perforation secondary to COVID-19: case reports and literature review. Medicine Baltimore. 2021; 100 (19): e25771. doi: 10.1097/MD.0000000000025771.

4. Filová M, Adamová Z. Colonic perforation in patients with COVID-19 pneumonia - case reports. Rozhl Chir. 2021; 100 (7): 353-356. doi: 10.33699/PIS.2021.100.7.

5. Gutiérrez-Lorenzo M, Cuadros-Martínez CM. Baricitinib en el tratamiento de infección por SARS-CoV-2 [Baricitinib in the treatment of SARS-CoV-2 infection]. Rev Esp Quimioter. 2020; 33 (4): 294-295. doi: 10.37201/req/047.2020.

6. Praveen D, Puvvada RC, M VA. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int J Antimicrob Agents. 2020; 55 (5): 105967. doi: 10.1016/j.ijantimicag.2020.105967.

7. Moreno-González G, Mussetti A, Albasanz-Puig A et al. A phase I/II clinical trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Trials. 2021; 22 (1): 116. doi: 10.1186/s13063-021-05072-4.